The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
Open accessAbstract
Objective: Develop a cerebrospinal fluid biomarker signature for mild Alzheimer's disease (AD) in Alzheimer's Disease Neuroimaging Initiative (ADNI) subjects. Methods: Amyloid‐β 1 to 42 peptide (Aβ 1–42), total tau (t‐tau), and tau phosphorylated at the threonine 181 were measured in (1) cerebrospinal fluid (CSF) samples obtained during baseline evaluation of 100 mild AD, 196 mild cognitive impairment, and 114 elderly cognitively normal (NC) subjects in ADNI; and (2) independent 56 autopsy‐confirmed AD cases and 52 age‐matched elderly NCs using a multiplex immunoassay. Detection of an AD CSF profile for t‐tau and Aβ 1–42 in ADNI subjects was achieved using receiver operating characteristic cut points and logistic regression models derived from the autopsy‐confirmed CSF data. Results: CSF Aβ 1–42 was the most sensitive biomarker for AD in the autopsy cohort of CSF samples: receiver operating characteristic area under the curve of 0.913 and sensitivity for AD detection of 96.4%. In the ADNI cohort, a logistic regression model for Aβ 1–42, t‐tau, and APO ε 4 allele count provided the best assessment delineation of mild AD. An AD‐like baseline CSF profile for t‐tau/Aβ 1–42 was detected in 33 of 37 ADNI mild cognitive impairment subjects who converted to probable AD during the first year of the study. Interpretation: The CSF biomarker signature of AD defined by Aβ 1–42 and t‐tau in the autopsy‐confirmed AD cohort and confirmed in the cohort followed in ADNI for 12 months detects mild AD in a large, multisite, prospective clinical investigation, and this signature appears to predict conversion from mild cognitive impairment to AD. Ann Neurol 2009
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A preponderance of evidence supports the interpretation that PIB uptake and CSF Aβ42 are reliable surrogate markers of amyloid plaque pathology in living subjects (15-19).”
From Human ApoE isoforms differentially regulate brain amyloid-β peptide clearance (2011) · cites this paper as [17]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Increased concentrations of extracellular soluble phosphorylated tau (p-tau) and total tau (t-tau) constitute a reliable index of this intracellular process in mild cognitive impairment due to AD2,3 and AD dementia.2,4”
From Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's disease (2022) · cites this paper as [4]
Experimental — accuracy not yet measuredIn the citing paper
“Abnormal CSF Aβ42 values were defined using the previously established cut-off of <192 ng/L57–59.”
From Earliest accumulation of β-amyloid occurs within the default-mode network and concurrently affects brain connectivity (2017) · cites this paper as [57]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hansson, O., Zetterberg, H., Buchhave, P., Londos, E., Blennow, K., & Minthon, L. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70355-6 · Cited by 1,700
Self-citationCSF markers for incipient Alzheimer's disease
Blennow, K., & Hampel, H. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00530-1 · Cited by 1,291
Self-citationMueller, S. G., Weiner, M. W., Thal, L. J., Petersen, R. C., Jack, C. R., Jagust, W., Trojanowski, J. Q., Toga, A. W., & Beckett, L. (2005) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2005.06.003 · Cited by 1,233
Self-citationFagan, A. M., Roe, C. M., Xiong, C., Mintun, M. A., Morris, J. C., & Holtzman, D. M. (2007) · Archives of Neurology · doi:10.1001/archneur.64.3.noc60123 · Cited by 897
Cell biology of protein misfolding: the examples of Alzheimer's and Parkinson's diseases
Selkoe, D. J. (2004) · Nature Cell Biology · doi:10.1038/ncb1104-1054 · Cited by 863
Consensus Report of the Working Group on: “Molecular and Biochemical Markers of Alzheimer’s Disease”
The Ronald and Nancy Reagan Research Institute of the Alzheimer’s Association and, & National Institute on Aging Working Group (1998) · Neurobiology of Aging · doi:10.1016/s0197-4580(98)00022-0 · Cited by 719
Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs
Forman, M. S., Trojanowski, J. Q., & Lee, V. M.-Y. (2004) · Nature Medicine · doi:10.1038/nm1113 · Cited by 715
Self-citationSunderland, T., Linker, G., Mirza, N., Putnam, K. T., Friedman, D. L., Kimmel, L. H., Bergeson, J., Manetti, G. J., Zimmermann, M., Tang, B., et al. (2003) · JAMA · doi:10.1001/jama.289.16.2094 · Cited by 656
Frontotemporal dementia: Clinicopathological correlations
Forman, M. S., Farmer, J., Johnson, J. K., Clark, C. M., Arnold, S. E., Coslett, H. B., Chatterjee, A., Hurtig, H. I., Karlawish, J. H., Rosen, H. J., et al. (2006) · Annals of Neurology · doi:10.1002/ana.20873 · Cited by 478
Self-citationGalasko, D., Chang, L., Motter, R., Clark, C. M., Kaye, J., Knopman, D., Thomas, R., Kholodenko, D., Schenk, D., Lieberburg, I., et al. (1998) · Archives of Neurology · doi:10.1001/archneur.55.7.937 · Cited by 442
Self-citation
Flagged first, then by citations
Research works printed but not linked: 1
- 10.1016/S1474-4422(03)00530-1 · DOI · Paper page
Cited by
Sorted by citations
Items 901–1,000 of 1,012
Zhao, Q., Liu, M., Ha, L., Zhou, Y., & Initiative, A. D. N. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.00486 · Cited by 39
Self-citationElman, J. A., Panizzon, M. S., Gustavson, D. E., Franz, C. E., Sanderson‐Cimino, M. E., Lyons, M. J., & Kremen, W. S. (2019) · Biological Psychiatry · doi:10.1016/j.biopsych.2019.12.021 · Cited by 36
Xu, W., Wei, F., Shen, X., Bi, Y., Ma, Y., Li, J., Dong, Q., Tan, L., & Yu, J. (2020) · Biological Psychiatry · doi:10.1016/j.biopsych.2020.07.004 · Cited by 35
Higher CSF sTNFR1-related proteins associate with better prognosis in very early Alzheimer’s disease
Hu, W. T., Ozturk, T. T., Kollhoff, A. L., Wharton, W., Howell, J. C., Initiative, A. D. N., Weiner, M. W., Aisen, P. S. S., Petersen, R. C., Jack, C. R., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24220-7 · Cited by 35
Self-citationComputerized tomographic study of normal Evans index in adult Nigerians
Hamidu, A. U., Olarinoye-Akorede, S. A., Ekott, D. S., Danborno, B., Mahmud, M. R., & Balogun, M. S. (2014) · Journal of Neurosciences in Rural Practice · doi:10.4103/0976-3147.143195 · Cited by 35
Paternicò, D., Galluzzi, S., Drago, V., Bocchio‐Chiavetto, L., Zanardini, R., Pedrini, L., Baronio, M., Amicucci, G., & Frisoni, G. B. (2012) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2011.10.003 · Cited by 34
Li, J., Zhang, Q., Chen, F., Yan, J., Kim, S., Wang, L., Feng, W., Saykin, A. J., Liang, H., & Shen, L. (2015) · BioMed Research International · doi:10.1155/2015/647389 · Cited by 34
Ly, J. V., Rowe, C. C., Villemagne, V. L., Zavala, J. A., Ma, H., Sahathevan, R., O'Keefe, G. J., Gong, S. J., Gunawan, R., Churilov, L. P., et al. (2012) · Stroke · doi:10.1161/strokeaha.111.636266 · Cited by 34
Lipidomic Analysis of Plasma Extracellular Vesicles Derived from Alzheimer’s Disease Patients
Krokidis, M. G., Pucha, K. A., Mustapić, M., Exarchos, T. P., Vlamos, P., & Kapogiannis, D. (2024) · Cells · doi:10.3390/cells13080702 · Cited by 34
Ringman, J. M., Gylys, K. H., Medina, L. D., Fox, M., Kepe, V., Flores, D. L., Apostolova, L. G., Barrio, J. R., Small, G., Silverman, D. H. S., et al. (2010) · Neuroscience Letters · doi:10.1016/j.neulet.2010.10.039 · Cited by 35
The influence of genetic variants in SORL1 gene on the manifestation of Alzheimer's disease
Louwersheimer, E., Ramı́rez, A., Cruchaga, C., Becker, T., Kornhuber, J., Peters, O., Heilmann‐Heimbach, S., Wiltfang, J., Jessen, F., Visser, P. J., et al. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.12.007 · Cited by 34
Liu, Y., Mattila, J., Muñoz‐Ruiz, M. Á., Paajanen, T. I., Koikkalainen, J. R., van Gils, M., Herukka, S., Waldemar, G., Lötjönen, J. M. P., Soininen, H. S., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055246 · Cited by 34
Self-citationBlood Biomarkers for Alzheimer’s Disease: Much Promise, Cautious Progress
Keshavan, A., Heslegrave, A., Zetterberg, H., & Schott, J. M. (2017) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-016-0241-0 · Cited by 34
Hornberger, J. C., Bae, J. P., Watson, I., Johnston, J., & Happich, M. (2016) · Current Medical Research and Opinion · doi:10.1080/03007995.2016.1277197 · Cited by 35
Tward, D. J., Sicat, C. S., Brown, T., Bakker, A., Gallagher, M., Albert, M., Miller, M. I., & Initiative, A. D. N. (2017) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2017.07.005 · Cited by 34
Self-citationTrombetta, B. A., Carlyle, B. C., Koenig, A. M., Shaw, L. M. J., Trojanowski, J. Q., Wolk, D. A., Locascio, J. J., & Arnold, S. E. (2018) · PLoS ONE · doi:10.1371/journal.pone.0193707 · Cited by 34
Self-citationA biomarker study in long-lasting amnestic mild cognitive impairment
Cerami, C., Dodich, A., Iannaccone, S., Magnani, G., Santangelo, R., Presotto, L., Marcone, A., Gianolli, L., Cappa, S. F., & Perani, D. (2018) · Alzheimer s Research & Therapy · doi:10.1186/s13195-018-0369-8 · Cited by 37
APOE Effect on Amyloid-β PET Spatial Distribution, Deposition Rate, and Cut-Points
Toledo, J. B., Habes, M., Sotiras, A., Bjerke, M., Yong Fan, A., Weiner, M. W., Shaw, L. M. J., Davatzikos, C. A., Trojanowski, J. Q., & Initiative, A. D. N. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-181282 · Cited by 36
Self-citationInflammatory pathway analytes predicting rapid cognitive decline in MCI stage of Alzheimer’s disease
Pillai, J. A., Bena, J., Bebek, G., Bekris, L. M., Bonner‐Jackson, A., Kou, L., Pai, A., Sørensen, L., Neilsen, M., Rao, S. M., et al. (2020) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51109 · Cited by 34
Clinical and biomarker trajectories in sporadic Alzheimer's disease: A longitudinal study
Wang, H.-F., Shen, X., Li, J., Suckling, J., Tan, C., Wang, Y., Feng, L., Zhang, C. M., Tan, L., Dong, Q., et al. (2020) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12095 · Cited by 36
Self-citationKononikhin, A. S., Zakharova, N. V., Semenov, S. D., Bugrova, A. E., Brzhozovskiy, A. G., Indeykina, M. I., Fedorova, Y. B., Колыхалов, И. В., Strelnikova, P. A., Ikonnikova, A. Y., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23147907 · Cited by 33
Suemoto, C. K., Santos, I. S., Bittencourt, M. S., Pereira, A. C., Goulart, A. C., Rundek, T., Passos, V. M. D. A., Lotufo, P. A., & Benseñor, I. M. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.10.008 · Cited by 33
Lewczuk, P., Lelental, N., Lachmann, I., Holzer, M., Flach, K., Brandner, S., Engelborghs, S., Teunissen, C. E., Zetterberg, H., Molinuevo, J. L., et al. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160448 · Cited by 33
Self-citationWang, H., Stewart, T., Toledo, J. B., Ginghina, C., Tang, L., Atik, A., Aro, P., Shaw, L. M., Trojanowski, J. Q., Galasko, D. R., et al. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-171013 · Cited by 33
Self-citationCerebrospinal Fluid Biomarkers for Alzheimer's Disease: More to Come?
Zetterberg, H., & Blennow, K. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-129035 · Cited by 34
Self-citationWhy therapies for Alzheimer’s disease do not work: Do we have consensus over the path to follow?
Amtul, Z. (2015) · Ageing Research Reviews · doi:10.1016/j.arr.2015.09.003 · Cited by 35
Quantitating Severity and Progression in Primary Progressive Aphasia
Dickerson, B. C. (2011) · Journal of Molecular Neuroscience · doi:10.1007/s12031-011-9534-2 · Cited by 35
Okonkwo, O. C. (2011) · Archives of Neurology · doi:10.1001/archneurol.2010.334 · Cited by 34
Initiative, A. D. N., Song, A., Yan, J., Kim, S., Risacher, S. L., Wong, A. K., Saykin, A. J., Shen, L., & Greene, C. S. (2016) · BioData Mining · doi:10.1186/s13040-016-0082-8 · Cited by 33
Self-citationInsel, P. S., Donohue, M., Mackin, R. S., Aisen, P. S. S., Hansson, O., Weiner, M. W., & Mattsson, N. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.08.017 · Cited by 35
Self-citationFalahati, F., Ferreira, D., Muehlboeck, J.-S., Eriksdotter, M., Simmons, A., Wahlund, L., & Westman, E. (2017) · NeuroImage: Clinical · doi:10.1016/j.nicl.2017.08.014 · Cited by 30
Preclinical effects of APOE ε4 on cerebrospinal fluid Aβ42 concentrations
Lautner, R., Insel, P. S., Skillbäck, T. B., Olsson, B., Landén, M., Frisoni, G. B., Herukka, S., Hampel, H. J., Wallin, A., Minthon, L., et al. (2017) · Alzheimer s Research & Therapy · doi:10.1186/s13195-017-0313-3 · Cited by 34
Self-citationBrown, C., Jiang, Y., Smith, C. D., & Gold, B. T. (2018) · Cortex · doi:10.1016/j.cortex.2018.04.006 · Cited by 33
Association of cerebrospinal fluid Neurogranin with Alzheimer’s disease
Initiative, A. D. N., & Wang, L. (2018) · Aging Clinical and Experimental Research · doi:10.1007/s40520-018-0948-3 · Cited by 32
Self-citationAutomation vs. Experience: Measuring Alzheimer’s Beta-Amyloid 1–42 Peptide in the CSF
Kollhoff, A. L., Howell, J. C., & Hu, W. T. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00253 · Cited by 33
Ma, L., Huang, Y., Wang, Z.-T., Li, J., Hou, X., Shen, X., Ou, Y., Dong, Q., Tan, L., Yu, J., et al. (2019) · Aging · doi:10.18632/aging.102496 · Cited by 34
Self-citationEndothelial‐derived plasma exosome proteins in Alzheimer’s disease angiopathy
Abner, E. L., Elahi, F. M., Jicha, G. A., Mustapić, M., Al‐Janabi, O. M., Kramer, J. H., Kapogiannis, D., & Goetzl, E. J. (2020) · The FASEB Journal · doi:10.1096/fj.202000034r · Cited by 34
Suzuki, K., Hirakawa, A., Ihara, R., Iwata, A., Ishii, K., Ikeuchi, T., Sun, C., Donohue, M., Iwatsubo, T., & Alzheimer's Disease Neuroimaging Initiative, J. A. D. N. I. (2020) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12007 · Cited by 32
Fernandes, A. S., Tábuas‐Pereira, M., Duro, D., Lima, M., Gens, H., Santiago, B., Durães, J., Almeida, M. R., Leitão, M. J., Baldeiras, I., et al. (2020) · Experimental Gerontology · doi:10.1016/j.exger.2020.111004 · Cited by 37
Plasma NT1 Tau is a Specific and Early Marker of Alzheimer's Disease
Mengel, D., Janelidze, S., Glynn, R. J., Liu, W., Hansson, O., & Walsh, D. M. (2020) · Annals of Neurology · doi:10.1002/ana.25885 · Cited by 32
Four subgroups based on tau levels in Alzheimer’s disease observed in two independent cohorts
ADNI, Duits, F. H., Wesenhagen, K. E. J., Ekblad, L. L., Wolters, E. E., Willemse, E. A. J., Scheltens, P., van der Flier, W. M., Teunissen, C. E., Visser, P. J., et al. (2021) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00713-3 · Cited by 34
Multiple Subtypes of Alzheimer’s Disease Base on Brain Atrophy Pattern
Zhang, B., Lin, L., Wu, S., & Al-Masqari, Z. (2021) · Brain Sciences · doi:10.3390/brainsci11020278 · Cited by 33
Zhang, Z., Cui, L., Huang, Y., Chen, Y., Li, Y., & Guo, Q. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.646414 · Cited by 33
Biological markers of Alzheimer?s disease
de Souza, L. C., Sarazin, M., Teixeira, A. L., Caramelli, P., dos Santos, A. M., & Dubois, B. (2014) · Arquivos de Neuro-Psiquiatria · doi:10.1590/0004-282x20130233 · Cited by 33
Monitoring Progression of Primary Progressive Aphasia: Current Approaches and Future Directions
Sapolsky, D., Domoto‐Reilly, K., Negreira, A. M., Brickhouse, M. J., McGinnis, S. M., & Dickerson, B. C. (2011) · Neurodegenerative Disease Management · doi:10.2217/nmt.11.2 · Cited by 31
Use of Alzheimer Disease Biomarkers
Petersen, R. C., & Trojanowski, J. Q. (2009) · JAMA · doi:10.1001/jama.2009.1073 · Cited by 33
Self-citationP50: A candidate ERP biomarker of prodromal Alzheimer׳s disease
Green, D. L., Payne, L., Robi Polikar, A., Moberg, P. J., Wolk, D. A., & Kounios, J. (2015) · Brain Research · doi:10.1016/j.brainres.2015.07.054 · Cited by 31
Progressive Supranuclear Palsy and Corticobasal Degeneration
Coughlin, D. G., Dickson, D. W., Josephs, K. A., & Litvan, I. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-51140-1_11 · Cited by 33
Leaver, K. R., & Poston, K. L. (2015) · Neuropsychology Review · doi:10.1007/s11065-015-9307-8 · Cited by 34
Chatterjee, M., del Campo, M., Morrema, T. H. J., de Waal, M. W. J., van der Flier, W. M., Hoozemans, J. J. M., & Teunissen, C. E. (2018) · Alzheimer s Research & Therapy · doi:10.1186/s13195-018-0383-x · Cited by 33
Riedel, B. C., Daianu, M., Steeg, G. V., Mezher, A. F., Salminen, L. E., Galstyan, A., Thompson, P. M., & Initiative, A. D. N. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00390 · Cited by 32
Self-citationInitiative, A. D. N., Ezzati, A., Zammit, A. R., Habeck, C. G., Hall, C. B., & Lipton, R. B. (2019) · Brain Imaging and Behavior · doi:10.1007/s11682-019-00115-6 · Cited by 31
Self-citationNonlinear biomarker interactions in conversion from mild cognitive impairment to Alzheimer's disease
Popescu, S. G., Whittington, A., Gunn, R. N., Matthews, P. M., Glocker, B., Sharp, D. J., Cole, J. H., & Initiative, A. D. N. (2020) · Human Brain Mapping · doi:10.1002/hbm.25133 · Cited by 30
Self-citationAD risk score for the early phases of disease based on unsupervised machine learning
Wang, Z., Tang, Z., Zhu, Y., Pettigrew, C. A., Soldan, A., Gross, A. L., & Albert, M. (2020) · Alzheimer s & Dementia · doi:10.1002/alz.12140 · Cited by 34
Khan, W., Aguilar, C., Kiddle, S. J., Doyle, O., Thambisetty, M., Muehlboeck, S., Sattlecker, M., Newhouse, S., Lovestone, S., Dobson, R., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0134368 · Cited by 32
Self-citationCerebrospinal fluid proteomic patterns discriminate Parkinson's disease and multiple system atrophy
Ishigami, N., Tokuda, T., Ikegawa, M., Komori, M., Kasai, T., Kondo, T., Matsuyama, Y., Nirasawa, T., Thiele, H., Tashiro, K., et al. (2012) · Movement Disorders · doi:10.1002/mds.24994 · Cited by 32
Fjell, A. M., Amlien, I. K., Westlye, L. T., Stenset, V. T. V., Fladby, T., Skinningsrud, A., Eilsertsen, D. E., Bjørnerud, A., & Walhovd, K. B. (2009) · NeuroImage · doi:10.1016/j.neuroimage.2009.09.029 · Cited by 32
Toledo, J. B., Korff, A., Shaw, L. M. J., Trojanowski, J. Q., Zhang, J., & Initiative, T. A. D. N. (2014) · Alzheimer s Research & Therapy · doi:10.1186/alzrt266 · Cited by 32
Self-citationOlder Adults Taking AT1-Receptor Blockers Exhibit Reduced Cerebral Amyloid Retention
Nation, D. A., Ho, J. K., & Yew, B. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-150487 · Cited by 32
Timmers, M., Barão, S., Broeck, B. V., Tesseur, I. C., Slemmon, J., Waepenaert, K. D., Bogert, J., Shaw, L. M. J., Engelborghs, S., Moechars, D., et al. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-160829 · Cited by 32
Self-citationPereira, J. B., Strandberg, T. O., Palmqvist, S., Volpe, G., van Westen, D., Westman, E., Hansson, O., & Initiative, A. D. N. (2017) · Cerebral Cortex · doi:10.1093/cercor/bhx294 · Cited by 33
Self-citationBarisano, G., Iv, M., Choupan, J., Gephart, M. H., Weiner, M. W., Aisen, P., Petersen, R. C., Jack, C. R., Jagust, W., Trojanowki, J. Q., et al. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105523 · Cited by 34
Self-citationChiang, G. C.-Y., Insel, P. S., Tosun, D., Schuff, N. W., Truran‐Sacrey, D., Raptentsetsang, S. T., Thompson, P. M., Reiman, E. M., Jack, C. R., Fox, N. C., et al. (2011) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2010.12.010 · Cited by 31
Self-citationHo, S., Xu, D., Wong, M. S., & Li, H. (2016) · Chemical Science · doi:10.1039/c5sc04115e · Cited by 31
McRae‐McKee, K., Evans, S., Hadjichrysanthou, C., Wong, M. M., de Wolf, F., & Anderson, R. M. (2019) · Scientific Reports · doi:10.1038/s41598-019-42632-w · Cited by 32
Ma, Y., Shen, X., Xu, W., Huang, Y., Li, H., Tan, L., Tan, C., Dong, Q., Tan, L., Yu, J., et al. (2020) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12041 · Cited by 30
Self-citationWhite matter hyperintensities and cognition across different Alzheimer's biomarker profiles
Lam, S., Lipton, R. B., Harvey, D. J., Zammit, A. R., Ezzati, A., & Initiative, A. D. N. (2021) · Journal of the American Geriatrics Society · doi:10.1111/jgs.17173 · Cited by 30
Self-citationBiological correlates of elevated soluble TREM2 in cerebrospinal fluid
Winfree, R. L., Dumitrescu, L. C., Blennow, K., Zetterberg, H., Gifford, K. A., Pechman, K. R., Jefferson, A. L., & Hohman, T. J. (2022) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2022.06.013 · Cited by 31
Self-citationRoberts, J. S., & Tersegno, S. M. (2010) · Future Neurology · doi:10.2217/fnl.10.31 · Cited by 32
Biomarkers in Alzheimer’s Disease
Riverol, M., & López, O. L. (2011) · Frontiers in Neurology · doi:10.3389/fneur.2011.00046 · Cited by 33
Tang, W. X., Huang, Q., Yao, Y., Wang, Y., Wu, Y., & Wang, Z.-Y. (2014) · Journal of Neural Transmission · doi:10.1007/s00702-014-1226-y · Cited by 32
Jellinger, K. A., Grazer, A., Petrovic, K. E., Ropele, S., Alpi, G., Kapeller, P., Ströbel, T., & Schmidt, R. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0712-z · Cited by 32
The Mental Status Examination in Patients With Suspected Dementia
Grossman, M., & Irwin, D. J. (2016) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000000298 · Cited by 32
Durazzo, T. C., Initiative, A. D. N., Korecka, M., Trojanowski, J. Q., Weiner, M. W., Hara, R. O., Ashford, J. W., & Shaw, L. M. J. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160413 · Cited by 32
Self-citationMcKenzie, C., Bucks, R. S., Weinborn, M., Bourgeat, P., Salvado, O., & Gavett, B. E. (2020) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2019.12.022 · Cited by 34
Use of Biomarkers in Clinical Trials of Alzheimer Disease
Wu, L., Rosa‐Neto, P., & Gauthier, S. G. (2011) · Molecular Diagnosis & Therapy · doi:10.1007/bf03256467 · Cited by 32
Sung, H. Y., Choi, B., Jeong, J. H., Kong, K. A., Hwang, J., & Ahn, J. (2016) · PLoS ONE · doi:10.1371/journal.pone.0153156 · Cited by 30
Ba, M., Li, X., Ng, K. P., Pascoal, T. A., Mathotaarachchi, S. S., Rosa‐Neto, P., Gauthier, S. G., & Initiative, A. D. N. (2017) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2016.12.005 · Cited by 34
Self-citationAmyloid pathology in the progression to mild cognitive impairment
Insel, P. S., Hansson, O., Mackin, R. S., Weiner, M. W., & Mattsson, N. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.12.018 · Cited by 29
Gangishetti, U., Howell, J. C., Perrin, R. J., Louneva, N., Watts, K. D., Kollhoff, A. L., Grossman, M., Wolk, D. A., Shaw, L. M. J., Morris, J. C., et al. (2018) · Alzheimer s Research & Therapy · doi:10.1186/s13195-018-0426-3 · Cited by 30
Self-citationEarly detection of subtle motor dysfunction in cognitively normal subjects with amyloid-β positivity
Mollica, M. A., Tort‐Merino, A., Navarra, J., Fernández‐Prieto, I., Valech, N., Olives, J., León, M., Lleó, A., Martínez‐Lage, P., Sánchez‐Valle, R., et al. (2019) · Cortex · doi:10.1016/j.cortex.2019.07.021 · Cited by 29
Park, S. A., Jung, J. M., Park, J. S., Lee, J. H., Park, B., Kim, H. J., Park, J., Chae, W. S., Jeong, J. H., Choi, S. H., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-64461-y · Cited by 32
Li, Z.-H., 650223，中国, 中. 昆., He, X., Li, H., He, R., Hu, X., 650204，中国, 中. 昆., 671000，中国, 大. 大., 200031，中国, 中., 650223，中国, 中. 昆., et al. (2020) · 动物学研究 · doi:10.24272/j.issn.2095-8137.2020.088 · Cited by 32
Stage, E., Svaldi, D. O., Phillips, M. L., Canela, V. H., Duran, T., Goukasian, N., Risacher, S. L., Saykin, A. J., Apostolova, L. G., & Initiative, A. D. N. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00647-w · Cited by 30
Self-citationInglese, M., Patel, N., Linton‐Reid, K., Loreto, F., Win, Z., Perry, R. J., Carswell, C. J., Grech‐Sollars, M., Crum, W. R., Lu, H., et al. (2022) · Communications Medicine · doi:10.1038/s43856-022-00133-4 · Cited by 30
Self-citationThe Feasibility of Early Alzheimer’s Disease Diagnosis Using a Neural Network Hybrid Platform
Yu, X., Srivastava, S., Huang, S., Hayden, E. Y., Teplow, D. B., & Xie, Y. (2022) · Biosensors · doi:10.3390/bios12090753 · Cited by 29
Guo, L., Alexopoulos, P., Eisele, T., Wagenpfeil, S., Kurz, A., & Perneczky, R. (2012) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-012-0349-0 · Cited by 33
Mackin, R. S., Initiative, A. D. N., Insel, P. S., Zhang, J., Mohlenhoff, B. S., Galasko, D. R., Weiner, M. W., & Mattsson, N. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-141287 · Cited by 31
Self-citationGrasso, G. (2018) · Mass Spectrometry Reviews · doi:10.1002/mas.21566 · Cited by 31
Lin, N., Gao, J., Mao, C., Sun, H., Lü, Q., & Cui, L. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.687053 · Cited by 29
Kurihara, M., Matsubara, T., Morimoto, S., Arakawa, A., Ohse, K., Kanemaru, K., Iwata, A., Murayama, S., & Saito, Y. (2024) · Acta Neuropathologica Communications · doi:10.1186/s40478-024-01758-3 · Cited by 29
Relationship Between Genetic Risk Factors and Markers for Alzheimer’s Disease Pathology
Elias-Sonnenschein, L. S., Bertram, L., & Visser, P. J. (2012) · Biomarkers in Medicine · doi:10.2217/bmm.12.56 · Cited by 28
Guo, H., Song, X., Vandorpe, R. A., Zhang, Y., Chen, W., Zhang, N., Schmidt, M. H., & Rockwood, K. J. (2013) · American Journal of Neuroradiology · doi:10.3174/ajnr.a3709 · Cited by 29
Diagnosis of Alzheimer's disease in Brazil: Supplementary exams
Caramelli, P., Teixeira, A. L., Buchpiguel, C. A., Lee, H. W., LIVRAMENTO, J. A., Fernandez, L. L., & Anghinah, R. (2011) · Dementia & Neuropsychologia · doi:10.1590/s1980-57642011dn05030004 · Cited by 30
Temporal association patterns and dynamics of amyloid-β and tau in Alzheimer’s disease
Initiative, A. D. N., Ower, A. K., Hadjichrysanthou, C., Gras, L. A., Goudsmit, J., Anderson, R. M., & de Wolf, F. (2017) · European Journal of Epidemiology · doi:10.1007/s10654-017-0326-z · Cited by 31
Self-citationBrain Aging and Late-Onset Alzheimer’s Disease: A Matter of Increased Amyloid or Reduced Energy?
Mecocci, P., Baroni, M., Senin, U., & Boccardi, V. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-179903 · Cited by 30
Falcón, C., Tucholka, A., Monté, G. C., Cacciaglia, R., Operto, G., Rami, L., Gispert, J. D., & Molinuevo, J. L. (2018) · NeuroImage Clinical · doi:10.1016/j.nicl.2018.04.016 · Cited by 29
Cognitive practice effects delay diagnosis of MCI: Implications for clinical trials
Sanderson‐Cimino, M. E., Elman, J. A., Tu, X. M., Gross, A. L., Panizzon, M. S., Gustavson, D. E., Bondi, M. W., Edmonds, E. C., Eglit, G. M. L., Eppig, J. S., et al. (2022) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12228 · Cited by 29
Self-citationThe proteinopenia hypothesis: Loss of Aβ42 and the onset of Alzheimer’s Disease
Espay, A. J., Herrup, K., Kepp, K. P., & Daly, T. P. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102112 · Cited by 31
Lachno, D. R., Emerson, J. K., Vanderstichele, H., Gonzales, C., Martényi, F., Konrad, R. J., Talbot, J. A., Lowe, S. L., Oefinger, P. E., & Dean, R. A. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-121075 · Cited by 29
Self-citation
Metadata
- Authors
- Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., Dean, R., Siemers, E., Potter, W., Lee, V. M. ‐., Trojanowski, J. Q., & Initiative, A. D. N.
- Affiliations
- University of Pennsylvania (US)
- Fujirebio (Belgium) (BE)
- University of California San Diego (US)
- Mayo Clinic (US)
- University of Gothenburg (SE)
- Pfizer (United States) (US)
- Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
- Eli Lilly (United States) (US)
- Corresponding author
- Shaw, Leslie M.
- ORCID
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2009-04
- Volume
- 65
- Issue
- 4
- Pages
- 403-413
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- PMC
- PMC2696350
- OpenAlex
- W2008301592
- Cited by
- 2,065
- References
- 31
- Citations by year
- 2026: 59 · 2025: 82 · 2024: 110 · 2023: 89 · 2022: 114 · 2021: 125 · 2020: 136 · 2019: 141 · 2018: 129 · 2017: 135 · 2016: 121 · 2015: 146 · 2014: 131 · 2013: 130 · 2012: 136
- FWCI
- 85.14
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Annals of Neurology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- University of Pennsylvania
- National Institutes of Health (5u01ag024904-10)
- National Institute on Aging (U01-AG-024904, AG 024904, P30AG010124, AG-10124, U19AG010483, U19AG024904)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Clinical Neurology › Cerebrospinal fluid and hydrocephalus
- Keywords
- Alzheimer's disease, cerebrospinal fluid biomarkers, amyloid-beta 42, total tau, mild cognitive impairment, conversion to Alzheimer's disease, APOE ε4, Alzheimer's Disease Neuroimaging Initiative
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Cognition Disorders, Diagnostic Imaging, Female, Humans, Male, Middle Aged, Peptide Fragments, Phosphorylation, Retrospective Studies, ROC Curve, Sensitivity and Specificity, Threonine, Cohort Studies, Biomarkers, Amyloid beta-Peptides, tau Proteins, Disease Progression, Statistics, Nonparametric, Area Under Curve, Apolipoprotein E4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
